Tag:
MET inhibition
Latest Headlines
Latest Headlines
Cancer therapy gets accelerated review at Exelixis
Exelixis and GlaxoSmithKline say they're hitting the gas on their program to develop XL880 as a "leading" MET inhibitor for cancer. Exelixis will review the therapy before
